Cisplatin treatment in pulmonary sarcoidosis: An In silico approach

[5] Despite increasing advances in studies, the diagnosis of sarcoidosis remains difficult with limited treatment options. Because of the lack of adequate experimental approaches, which are time consuming and expensive, improving bioinformatic techniques for defining potential miRNA-disease associat...

Full description

Saved in:
Bibliographic Details
Published in:National journal of physiology, pharmacy and pharmacology pharmacy and pharmacology, 2020, Vol.10 (10), p.1-904
Main Authors: Denkçeken, Tuba, Pala, Elif, Benlier, Necla
Format: Article
Language:English
Subjects:
Accuracy
Chemotherapy
Discriminant analysis
Disease
Drugs
Fatty acids
Gene expression
Methods
MicroRNAs
Mortality
Open source software
Principal components analysis
Sarcoidosis
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:[5] Despite increasing advances in studies, the diagnosis of sarcoidosis remains difficult with limited treatment options. Because of the lack of adequate experimental approaches, which are time consuming and expensive, improving bioinformatic techniques for defining potential miRNA-disease associations become essential. The GSE34608GPL7731_series_matrix.txt.gz microRNA expression profile was downloaded from the GEO database, consisting of eight pulmonary sarcoidosis patients (four females and four males, aged 42 ± 16.4 years) and eight healthy controls (five females and three males, aged 50 ± 12.6 years). Since our in silico study does not include neither animal nor human materials, no ethical committee approval was required. [...]we performed PCA again by applying the "prcomp" which was achieved by 1st finding the direction that has the largest variance (PC1: 96.3%) and finding the following directions. [...]it was identified that these genes were closely associated with cisplatin.
ISSN:2320-4672
2231-3206
DOI:10.5455/njppp.2020.10.07193202024072020